Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (101-110 of 280) with videos related to

Pageof 28
Sort By:
Clinical and Experimental Rheumatology|July 10, 2019
Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?Sara Freitas, Marta Mozo Ruiz, Antonio Costa Carneiro, et al.
Clinical Medicine (London, England)|April 10, 2014
A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experienceEsha Abrol, Cristina González-Pulido, Juan M Praena-Fernández, et al.
Arthritis Care & Research|July 19, 2016
Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum ImmunoglobulinsVenkat Reddy, Lina Martinez, David A Isenberg, et al.
Nature Reviews. Rheumatology|April 11, 2023
Precision medicine in systemic lupus erythematosusSerena Fasano, Alessandra Milone, Giovanni Francesco Nicoletti, et al.
Journal of Clinical Medicine|May 13, 2026
Anatomy of a Cohort: 40-Year Follow-Up of a Sjögren's CohortBlanca Viejo-Sosa, Uxía Couto-Lareo, Mònica Angerri-Nadal, et al.
Rheumatology (Oxford, England)|July 9, 2021
Can we predict if patients with SLE will require more than one cycle of rituximab?Raquel Fernández González, Rym Abida, Eugeniu Gisca, et al.
Clinical and Experimental Rheumatology|July 12, 2022
A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndromePedro Gaspar, Filipa Farinha, Zara Sayar, et al.
Arthritis and Rheumatism|March 17, 2004
Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?Lesley J Mason, Chelliah T Ravirajan, Anisur Rahman, et al.
Rheumatology (Oxford, England)|May 15, 2025
Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosusAmanda da Silva Brito, Sofia Miranda, Teresa Moitinho de Almeida, et al.
Immunity|March 13, 2012
Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cellsAnneleen Bosma, Azza Abdel-Gadir, David A Isenberg, et al.
Pageof 28

Showing results (101-110 of 280) with videos related to

Sort By:
Pageof 28
Clinical and Experimental Rheumatology|July 10, 2019
Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?Sara Freitas, Marta Mozo Ruiz, Antonio Costa Carneiro, et al.
Clinical Medicine (London, England)|April 10, 2014
A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experienceEsha Abrol, Cristina González-Pulido, Juan M Praena-Fernández, et al.
Arthritis Care & Research|July 19, 2016
Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum ImmunoglobulinsVenkat Reddy, Lina Martinez, David A Isenberg, et al.
Nature Reviews. Rheumatology|April 11, 2023
Precision medicine in systemic lupus erythematosusSerena Fasano, Alessandra Milone, Giovanni Francesco Nicoletti, et al.
Journal of Clinical Medicine|May 13, 2026
Anatomy of a Cohort: 40-Year Follow-Up of a Sjögren's CohortBlanca Viejo-Sosa, Uxía Couto-Lareo, Mònica Angerri-Nadal, et al.
Rheumatology (Oxford, England)|July 9, 2021
Can we predict if patients with SLE will require more than one cycle of rituximab?Raquel Fernández González, Rym Abida, Eugeniu Gisca, et al.
Clinical and Experimental Rheumatology|July 12, 2022
A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndromePedro Gaspar, Filipa Farinha, Zara Sayar, et al.
Arthritis and Rheumatism|March 17, 2004
Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?Lesley J Mason, Chelliah T Ravirajan, Anisur Rahman, et al.
Rheumatology (Oxford, England)|May 15, 2025
Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosusAmanda da Silva Brito, Sofia Miranda, Teresa Moitinho de Almeida, et al.
Immunity|March 13, 2012
Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cellsAnneleen Bosma, Azza Abdel-Gadir, David A Isenberg, et al.
Pageof 28